Children's Medical Center Corporation

Entremed, Inc.

Celgene Corporation

Jamshed H Shah

Robert J D'Amato

Anthony Treston

Shawn J Green

Gregory E Agoston

John W Madsen

Theresa Marie LaVallee

Glenn M Swartz, Jr

Glenn M Swartz

Kimberly A Hunsucker

Victor S Pribluda

John Rougas

Barry P Conner

Adonia E Papathanassiu

William E Fogler

Taturo Udagawa

Victor Pribdula

Lita Suwandi

Christopher J Herbstritt

Xiaoguo H Zhan

Robert J D'amato

Victor Pribluda

Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ris selected from &#x2014;OCH, &#x2014;OCHCHor &#x2014;CCCH; and Z is selected from &#x3e;C(H)&#x2014;OH, &#x3e;C(H)&#x2014;O-alkyl, &#x3e;C(H)&#x2014;O-sulfamate, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.

Methods of treating disease states using antiangiogenic agents

The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(&#x2212;)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.

Synthesis of 4-amino-thalidomide enantiomers

Method of synthesis of 4-amino-thalidomide enantiomers

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.

Methods and compositions for treating an ocular neovascular disease

Antiangiogenic agents

Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.

Estradiol derivatives and pharmaceutical compositions using same

2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is particularly suitable for clinical use in humans. The purification methods of the invention involve the use of liquid-solid chromatography (LSC) to separate 2-ME2 from other compounds. The chromatographic media is preferably silica. The solvent system comprises a non-polar solvent, such as chloroform, and a polar solvent, such as methanol.

Methods of using 2-methoxyestradiol of high purity

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator

Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.

The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(&#x2212;)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.

Methods of treating undesired angiogenesis with 2-methyl-EM-138

Compositions comprising purified 2-methoxyestradiol and methods of producing same

The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(&plus;)-2-methyl-2-phthalimidinoglutaric acid and (S)-(&minus;)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.

Analogs of 2-Phthalimidinoglutaric acid

Methods and compositions for inhibition of angiogenesis with EM-138

The present invention relates to inhibition of angiogenesis and the treatment of diseases mediated by angiogenesis. Particularly, the invention relates to the inhibition of neovascularization and the treatment of cancer. The invention further relates to the use of cytochalasin derivatives for the inhibition of angiogenesis and the treatment of angiogenesis associated diseases.

Methods for the inhibition of angiogenesis with arglabin

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprise the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.

Growing community of inventors

Brookeville, MD, United States of America

Jamshed H Shah